etrumadenant + sacituzumab govitecan

**Etrumadenant + sacituzumab govitecan** is an investigational combination therapy for the treatment of cancers, particularly those expressing TROP-2, such as various solid tumors including breast cancer. Etrumadenant is an oral, small molecule dual antagonist of the adenosine A2A and A2B receptors, which functions to reverse adenosine-mediated immunosuppression in the tumor microenvironment. Sacituzumab govitecan is an antibody-drug conjugate (ADC) composed of a humanized anti-TROP-2 monoclonal antibody conjugated to the cytotoxic topoisomerase I inhibitor SN-38 via a hydrolyzable linker, targeting and killing TROP-2-expressing tumor cells through internalization and DNA damage-induced apoptosis. The combination is being studied to exploit both immunomodulatory and direct cytotoxic mechanisms for enhanced anticancer efficacy[1].

Other names

sacituzumab govitecan-hziyhRS 7SN38hRS7SN38hRS-7SN38hRS7-SN38hRS-7-SN38hRS 7-SN38IMMU132IMMU-132IMMU 132